GlassScriptPhysician profile
Nicolette B Naso
NPI 1871550236
$8,105.95
in general payments reported to CMS, 2019-2025
39 companies · $1,157 in 2025
The $1,157 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $970 · 2021: $1,202 · 2022: $1,040 · 2023: $1,242 · 2024: $1,618 · 2025: $1,157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,016.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,025.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $867.38 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Janssen Pharmaceuticals, INC | $805.14 | 2019-2024 | Xarelto |
| Pfizer INC. | $692.80 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $659.77 | 2019-2025 | Lifevest |
| Amgen INC. | $587.73 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.01 | 2020-2025 | Jardiance |
| Boston Scientific Corporation | $459.08 | 2019-2025 | Watchman Flx, Watchman Access System, Wavewriter Alpha Prime 16 |
| E.R. Squibb & Sons, L.L.C. | $445.38 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $366.24 | 2021-2025 | Verquvo, Capvaxive |
| Chiesi USA, INC. | $319.45 | 2019-2025 | Kengreal, Cleviprex |
| Esperion Therapeutics, INC. | $261.19 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $175.18 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $148.79 | 2019-2023 | |
| Alnylam Pharmaceuticals INC. | $76.41 | 2021-2025 | Onpattro, Amvuttra |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $70.42 | 2025 | Attruby |
| Atricure, INC. | $65.10 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Impulse Dynamics (USA) INC. | $63.19 | 2025 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $60.29 | 2023-2024 | Inpefa |
| Shockwave Medical, INC | $58.31 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Philips North America LLC | $55.28 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $41.38 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $37.70 | 2024 | Arcalyst |
| Amryt Pharma Holdings LTD | $25.35 | 2021 | |
| Inspire Medical Systems, INC. | $25.31 | 2024 | Inspire |
| Abbott Laboratories | $24.81 | 2025 | Amplatzer Amulet |
| Angiodynamics, INC. | $23.67 | 2025 | Alphavac |
| Scpharmaceuticals INC. | $23.48 | 2024 | |
| Edwards Lifesciences Corporation | $23.12 | 2020 | |
| Cvrx, INC. | $21.50 | 2025 | Barostim Neo System |
| Cordis US Corp. | $17.00 | 2025 | Mynx Control Venous |
| Terumo Medical Corporation | $16.30 | 2020 | |
| Portola Pharmaceuticals, LLC | $16.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.27 | 2025 | |
| Lundbeck LLC | $14.62 | 2019 | |
| Daiichi Sankyo INC. | $14.59 | 2025 | Injectafer |
| Vifor Pharma, INC. | $13.03 | 2020 | |
| Hikma Pharmaceuticals USA | $12.63 | 2019 | |
| Medtronic Vascular, INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolette Naso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.